BeneFix, Inc.

LANCASTER, PA · Founded 2015 · CIK 0001700757 · Biotech

Recombinant coagulation factor IX (BeneFix) for hemophilia B treatment

benefix.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$8.6M
3 Form D · Aug 2020
74 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$485,000
Private capital raisedForm D · SEC$4,220,597
Private capital raisedForm D · SEC$3,850,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1582PARMEDICS, INC——
1583Versa Integrated Solutions, Inc.——
1584Stem Biotech LLC—$100M
1585BeneFix, Inc.—$8.6M
1586H-CYTE, INC.—$11M
1587REGENERIX LLC——
1588CHEMILY, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • Todd BartosExecutive Officer
  • Glen BressnerDirector
  • Jeffrey DavisonDirector
  • Steve HeilenmanExecutive Officer
  • Michael JemisonDirector
  • Adam MathisDirector
  • Matt RanauroExecutive Officer
  • Matthew RanauroDirector · Executive Officer · Promoter
  • Matthew RayDirector
  • Lee Shand SnyderExecutive Officer
  • Benjamin SloopDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.